Biosensors Market by Application - 2022 | MarketsandMarkets
The biosensors market has witnessed significant growth in the last few years. Currently, North America is the leading market for biosensors, followed by Europe. Players such as Abbott Point of Care Inc. (US), LifeScan, Inc. (US), Bayer Healthcare AG (Germany), and Medtronic Inc. (US) have their manufacturing facilities across these two geographies
Download PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=798
Some of the major players operating in the biosensors market include Abbott Point of Care Inc. (US), Medtronic, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Siemens AG (Germany), LifeScan, Inc. (US), LifeSensors Inc. (US), Nova Biomedical Corp. (US), Acon Laboratories Inc. (US), Universal Biosensors (Australia), Pharmaco-Kinesis Corporation (PKC) (US), Bayer Healthcare AG (Germany), Biacore (UK), Bio-Rad Laboratories Inc. (US), Biosensors International Ltd. (Singapore), Ercon, Inc. (US), DuPont (US), and Sysmex Corporation (Japan).
Medtronic Inc. (US) develops, manufactures, and markets medical devices, therapies, and services used in the treatment of heart, spinal, neurological, vascular, and diabetic conditions. The company has a well-established market presence in more than 140 countries worldwide. Moreover, to expand its geographic footprint, the company focuses on product approvals from various organizations and regulatory bodies. The company has adopted strategies such as acquisitions, expansions, and new product launches to grow in the market. In October 2015, Medtronic, Inc.’s (US) Coronary & Structural Heart division acquired Twelve, Inc. (US), a medical device company that develops transcatheter mitral valve replacement devices.
Universal Biosensors, Inc. (Australia) is a diversified technology and biosensors company, serving customers worldwide. The company provides medical diagnostics services and is engaged in the R&D and manufacturing of in-vitro diagnostic test devices for consumer and professional point-of-care use. It uses the electrochemical cell technology platform to develop point-of-care testing systems for different markets, including coagulation testing, blood glucose, and other electrochemical-cell based tests. The company exhibits the technology platform for markets with substantial commercial potential for enzymatic, immunoassay, and molecular diagnostic point-of-care tests.
Universal Biosensors, Inc. (Australia) has developed a blood glucose test in collaboration with LifeScan, Inc. (US), and a coagulation PT-INR test in collaboration with Siemens, which are now sold by LifeScan, Inc. (US) and Siemens Healthcare Diagnostics, Inc. (US), respectively. The major competitors of the company include Beckman Coulter, Inc. (US), Rochester Medical Corporation (US), and Abbott Laboratories (US).
No comments: